Evolving Concepts in Multiple Sclerosis Disease Progression: The impact of peripheral and centrally-driven neuroinflammation
- Examine the cellular mechanisms involved in peripherally- and CNS-derived inflammation and pathological drivers of “smouldering” MS.
- Describe the evolving understanding of the immune pathologies underlying MS progression and disability accumulation, and how these will be assessed in new clinical trials.
- Discuss BTK inhibitors, a new therapeutic class that may address multiple sources of inflammation.
- Review emerging fluid biomarkers for indication of MS disease progression and activity.
This program seeks to present the emerging understanding of MS as being driven by two parallel processes of peripherally-initiated inflammatory injury and CNS-compartmentalized injury. Under this concept, it is suggested that neurodegeneration driven primarily by CNS-compartmentalized inflammation occurs early and predicts the accumulation of disability in patients living with MS, independent of relapses—also referred to as smouldering MS.
Leveraging an expert panel, this program will explore the neuropathological drivers of centrally-driven inflammation, clinical impact on disability accumulation and fluid biomarkers that can help identify this clinical worsening.